GPR87 Antibody

What is GPR87 and what makes it a significant target for cancer research?

GPR87 is a G protein-coupled receptor that demonstrates specific expression patterns in various tumor types while exhibiting minimal expression in normal tissues. This tumor-specific expression profile makes it an attractive candidate for targeted cancer therapies. GPR87 has been identified as significantly upregulated in multiple cancer types, including lung cancer (70% of studied cases), pancreatic ductal adenocarcinoma (PDA), and malignant pleural mesothelioma (MPM), where it showed 100% high expression in clinical samples .

The receptor has been demonstrated to regulate cancer cell proliferation, inhibit apoptosis, and contribute to tumor progression through multiple signaling pathways . Its cell surface location and role in promoting cancer cell viability make it particularly valuable as a therapeutic target that can be accessed without requiring intracellular delivery mechanisms .

What detection methods are most effective for GPR87 expression analysis in clinical specimens?

Immunohistochemistry (IHC) remains the gold standard for detecting GPR87 expression in clinical specimens. When performing IHC for GPR87, researchers should consider these methodological parameters:

For optimal results, tissue-specific titration is essential, as sensitivity varies between sample types . Recent studies have employed GPR87 antibodies with detection rates of 54% in lung cancer specimens and 100% in MPM samples . When evaluating expression levels, researchers should employ standardized scoring systems that account for both staining intensity and percentage of positive cells.

How should researchers validate GPR87 antibody specificity before experimental use?

Validating antibody specificity is critical for ensuring reliable experimental outcomes. A comprehensive validation protocol should include:

• Western blot analysis using both GPR87-overexpressing and knockdown cell lines to confirm band specificity at the expected molecular weight (recommended antibody dilution: 1:500) .

• Implementing positive and negative controls in each experiment - GPR87-high expressing cell lines (such as BXPC-3 and Capan-2 for pancreatic cancer models) and GPR87-low expressing lines (such as SW1990 and Panc10.05) .

• Conducting peptide competition assays where pre-incubation of the antibody with the immunizing peptide should abolish specific staining.

• Cross-validation using multiple detection methods (e.g., IHC results should correlate with mRNA expression levels from qPCR or RNA-seq data) .

• Confirming reactivity with the species under investigation - the commonly used antibodies show reactivity with both human and mouse GPR87 .

What are the optimal protocols for using GPR87 antibodies in cancer stem cell research?

GPR87 has been implicated in cancer stem cell (CSC) maintenance and expansion, particularly in pancreatic ductal adenocarcinoma. When investigating GPR87's role in CSCs, researchers should implement these methodological approaches:

• Sphere formation assay: Culture cells in suspension at low density (500 cells/mL) in serum-free media supplemented with growth factors. GPR87-overexpressing cells typically show approximately 6% sphere generation frequency compared to 1.6% in GPR87-knockdown cells .

• Side population (SP) assay: Flow cytometric analysis using Hoechst 33342 dye to identify cells with stem-like properties. GPR87 overexpression significantly increases the SP-positive population .

• CSC marker expression analysis: Quantitative PCR assessment of stemness markers including CD133, EpCAM, CD24, CD44, and MET, which show correlation with GPR87 expression levels .

• Serial passage experiments: Assess self-renewal capacity through consecutive sphere generations, monitoring both sphere size and cell number per sphere over time (typically 7-14 days per passage) .

• Antibody validation using both western blot (1:500 dilution) and immunofluorescence (1:100-1:200) to confirm expression in stem-like subpopulations .

How can researchers effectively design GPR87 knockdown experiments?

When designing GPR87 knockdown experiments, consider these methodological recommendations:

• Vector selection: Adenoviral vectors carrying short hairpin RNAs (shRNAs) targeting GPR87 (Ad-shGPR87) have demonstrated effective knockdown with significant antitumor effects both in vitro and in vivo .

• Control design: Include both non-targeting shRNA controls and empty vector controls to differentiate between specific GPR87 knockdown effects and non-specific responses to viral delivery .

• Knockdown verification protocol:

  • mRNA level: Real-time RT-PCR using TRNzol Reagent for RNA isolation and FastKing one-step RT-PCR Kit for cDNA synthesis

  • Protein level: Western blot analysis using anti-GPR87 antibody (1:500 dilution)

  • Functional validation: Assess changes in downstream signaling pathways (NF-κB, JAK2/STAT3)

• Assessment timeline: Monitor knockdown efficiency at multiple timepoints (24h, 48h, 72h) post-transfection to determine optimal experimental windows .

• Transfection protocol: For cell lines difficult to transfect, Lipofectamine 3000 has shown efficacy in delivering GPR87-targeting constructs with minimal toxicity .

What methodology is required for near-infrared photoimmunotherapy (NIR-PIT) targeting GPR87?

Near-infrared photoimmunotherapy represents an emerging therapeutic approach for GPR87-positive tumors. Researchers investigating this technology should implement these methodological considerations:

• Antibody-photosensitizer conjugation:

  • Humanized anti-GPR87 antibody should be conjugated with IRDye700DX (IR700)

  • Conjugation ratio should be optimized (typically 3-4 molecules of IR700 per antibody)

  • Purification using Sephadex G50 column chromatography is recommended

• In vitro NIR-PIT protocol:

  • Cell incubation: 10 μg/mL of conjugate for 6 hours

  • Irradiation: Near-infrared light at 690 nm (5-20 J/cm²)

  • Controls: Include unconjugated antibody with irradiation and conjugate without irradiation

• In vivo application parameters:

  • Dosing: 100 μg of conjugate per mouse (for ~20g mouse)

  • Administration: Intravenous injection via tail vein

  • Light application: 50-100 J/cm² at 690 nm following peak accumulation (typically 24h post-injection)

• Therapeutic assessment:

  • Monitor tumor size, bioluminescence for luciferase-expressing tumors

  • Histological evaluation of treated tumors for necrosis and apoptosis

  • Assessment of systemic toxicity through blood chemistry and histopathology of major organs

How do experimental results of GPR87 inhibition differ between cancer models?

GPR87 inhibition produces varied outcomes across different cancer models, with important considerations for experimental design:

When designing comparative studies across cancer types, researchers should standardize inhibition methods while adapting assessment parameters to model-specific endpoints .

What signaling pathways should be evaluated when studying GPR87's functional role?

GPR87 modulates multiple downstream signaling pathways that contribute to its oncogenic functions. A comprehensive evaluation should include:

• NF-κB pathway: GPR87 activates NF-κB signaling in pancreatic cancer, promoting proliferation, angiogenesis, and chemoresistance. Assess through phospho-IκB, nuclear p65 translocation, and NF-κB reporter assays .

• JAK2/STAT3 pathway: GPR87 forms a complex with JAK2, leading to STAT3 phosphorylation. Evaluate using phospho-specific antibodies (p-STAT3 Tyr705, p-JAK2 Tyr1007-1008) with western blot analysis (recommended dilutions: anti-p-STAT3 1:2,000, anti-STAT3 1:1,000, anti-p-JAK2 1:1,000, anti-JAK2 1:1,000) .

• KRAS and c-Myc expression: GPR87 inhibition significantly decreases both KRAS and c-Myc expression in lung cancer models, suggesting a regulatory connection. qPCR and western blot analyses are recommended for assessment .

• Lysophosphatidic acid (LPA) signaling: As GPR87 functions as an LPA receptor, researchers should evaluate downstream effects including calcium flux, ERK1/2 phosphorylation, and cAMP modulation .

• For mechanistic studies, co-immunoprecipitation experiments using anti-FLAG (1:1,000) and anti-HA (1:2,000) antibodies can identify GPR87 interaction partners .

What methodological challenges exist in developing humanized antibodies against GPR87?

Developing effective humanized anti-GPR87 antibodies presents several technical challenges:

• Epitope selection: Identifying conserved epitopes that maintain high specificity while reducing immunogenicity requires careful antibody engineering. Researchers typically start with mouse anti-GPR87 antibodies generated through standard hybridoma methods and transfer complementarity-determining regions (CDRs) to human antibody frameworks .

• Humanization process validation: Humanized antibodies must be rigorously tested for:

  • Retention of binding affinity (no more than 4-fold reduction acceptable)

  • Target specificity across multiple tissue types

  • Reduced human anti-mouse antibody (HAMA) response potential

  • Proper effector functions if therapeutic applications are intended

• Functional assessment: Humanized antibodies should demonstrate comparable or superior functional characteristics compared to their murine counterparts when used for:

  • Imaging applications

  • NIR-PIT conjugation

  • Antibody-drug conjugate development

  • Diagnostic applications

• Production challenges: Expression systems for humanized antibodies require optimization for:

  • Yield maximization

  • Proper glycosylation patterns

  • Minimization of aggregation

  • Lot-to-lot consistency

How can researchers optimize immunohistochemical detection of GPR87 in tissue microarrays?

When optimizing GPR87 detection in tissue microarrays (TMAs), researchers should consider these methodological refinements:

• Fixation considerations: Formalin-fixed paraffin-embedded (FFPE) tissues require optimized antigen retrieval. Comparative testing shows TE buffer (pH 9.0) typically yields stronger staining than citrate buffer (pH 6.0) for GPR87 .

• Antibody selection: Polyclonal antibodies (such as 25999-1-AP) offer higher sensitivity for detecting varied epitopes but may have higher background. Dilution optimization (start with 1:50-1:500 range) is essential for each new TMA batch .

• Staining protocol modifications:

  • Extended primary antibody incubation (overnight at 4°C) improves signal-to-noise ratio

  • Signal amplification systems (such as tyramide signal amplification) may be required for low-expressing samples

  • Multiplex staining approaches allow co-localization studies with other tumor markers

• Controls and validation:

  • Include known GPR87-positive tissues (bladder cancer) as positive controls

  • Use isotype-matched irrelevant antibodies as negative controls

  • Validate with western blot of representative samples from the cohort

• Scoring systems: Implement semi-quantitative scoring combining intensity (0-3+) and percentage of positive cells to generate H-scores or quick scores for statistical analysis .

What are the experimental considerations when investigating GPR87 in cancer stem cell populations?

Investigating GPR87 in cancer stem cell populations requires specific methodological considerations:

• Enrichment strategies: Multiple approaches should be compared for CSC isolation:

  • FACS sorting based on established markers (CD133, CD44, CD24)

  • Sphere formation under serum-free conditions

  • Aldehyde dehydrogenase (ALDH) activity

  • Side population analysis using Hoechst 33342

• Validation requirements:

  • Self-renewal capacity through serial passaging (minimum 3 generations)

  • Multi-lineage differentiation potential

  • Enhanced tumorigenicity in limiting dilution assays

  • Resistance to conventional therapies

• GPR87 functional assessment:

  • Gain-of-function studies through overexpression in GPR87-low cells (SW1990, Panc10.05)

  • Loss-of-function studies in GPR87-high cells (BXPC-3, Capan-2)

  • Cell tracking in sphere formation assays to distinguish between proliferation and true stemness effects

• Technical challenges:

  • CSC populations often represent <5% of total tumor cells, requiring highly sensitive detection methods

  • Phenotypic plasticity necessitates dynamic tracking approaches rather than endpoint analyses

  • In vivo validation through limited dilution transplantation assays (100-1000 cells) is essential to confirm true stemness properties

How do in vitro and in vivo models compare when evaluating GPR87-targeted therapies?

The translation between in vitro and in vivo findings presents several important considerations for GPR87-targeted research:

For translational studies, researchers should implement both subcutaneous xenograft models (for initial efficacy assessment) and orthotopic models (for microenvironment interactions) .

What factors should be considered when interpreting conflicting data on GPR87 ligands?

The identity of GPR87's endogenous ligand remains controversial, with several studies reporting different findings. When evaluating contradictory results, researchers should consider:

• Methodological differences:

  • Receptor activation assays vary in sensitivity (calcium flux, β-arrestin recruitment, cAMP modulation)

  • Expression systems (stable vs. transient transfection) affect receptor density and coupling

  • Cell background influences G-protein coupling preferences

• Validation approaches:

  • Dose-response relationships should be established for putative ligands

  • Competitive binding assays with known ligands provide structural insights

  • Receptor mutants can clarify binding pocket requirements

  • Cross-desensitization studies help identify shared signaling mechanisms

• Physiological context:

  • Tissue-specific cofactors may modify ligand recognition

  • Post-translational modifications alter receptor conformation

  • Receptor heteromerization changes pharmacological properties

• The most substantial evidence supports lysophosphatidic acid (LPA) as a GPR87 ligand, though its binding affinity and specificity parameters require further characterization .

To resolve discrepancies, researchers should implement multiple complementary approaches and standardize experimental conditions when comparing results across studies.